Press Releases :: Algernon Pharmaceuticals Inc. (AGN)

Jan 19, 2021 8:03am EST

Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

Jan 11, 2021 8:00am EST

Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment

Jan 07, 2021 8:00am EST

Algernon Pharmaceuticals Announces Plans for 2021

Dec 30, 2020 8:00am EST

Algernon Pharmaceuticals Provides Year End Summary of Key Activities

Dec 24, 2020 11:42am EST

Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Dec 23, 2020 7:40pm EST

Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants

Dec 21, 2020 8:00am EST

Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast

Dec 17, 2020 8:00am EST

Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data

Dec 16, 2020 7:43pm EST

Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Dec 15, 2020 8:15am EST

Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study

rss_feed News RSS

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company.

Sign up for our News Releases and Updates

Head Office

Suite 400 - 601 West Broadway
Vancouver, British Columbia V5Z 4C2

Follow Us On

© Algernon Pharmaceuticals Inc. - All Rights Reserved